ESMO 2022 | Current first-line therapies for patients with advanced adrenocortical carcinoma

Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the current treatment options in advanced adrenocortical carcinoma. As this form of cancer is relatively rare and no standard of care exists. Dr Campbell additionally highlights the potential role of immunotherapy, with several Phase II trials assessing pembrolizumab have shown promising results. However, Phase III studies are needed to accurately evaluate their efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.